These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23876857)

  • 1. PopGen: A virtual human population generator.
    McNally K; Cotton R; Hogg A; Loizou G
    Toxicology; 2014 Jan; 315():70-85. PubMed ID: 23876857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprint of PopGen: A virtual human population generator.
    McNally K; Cotton R; Hogg A; Loizou G
    Toxicology; 2015 Jun; 332():77-93. PubMed ID: 25921244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A probabilistic model of human variability in physiology for future application to dose reconstruction and QIVIVE.
    McNally K; Loizou GD
    Front Pharmacol; 2015; 6():213. PubMed ID: 26528180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment.
    Wetmore BA
    Toxicology; 2015 Jun; 332():94-101. PubMed ID: 24907440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.
    Wetmore BA; Allen B; Clewell HJ; Parker T; Wambaugh JF; Almond LM; Sochaski MA; Thomas RS
    Toxicol Sci; 2014 Nov; 142(1):210-24. PubMed ID: 25145659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.
    Yoon M; Campbell JL; Andersen ME; Clewell HJ
    Crit Rev Toxicol; 2012 Sep; 42(8):633-52. PubMed ID: 22667820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards.
    El-Masri H; Kleinstreuer N; Hines RN; Adams L; Tal T; Isaacs K; Wetmore BA; Tan YM
    Toxicol Sci; 2016 Jul; 152(1):230-43. PubMed ID: 27208077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.
    Kedderis GL; Lipscomb JC
    Toxicol Ind Health; 2001 Jun; 17(5-10):315-21. PubMed ID: 12539878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving from external exposure concentration to internal dose: duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose.
    Simmons JE; Evans MV; Boyes WK
    J Toxicol Environ Health A; 2005 Jun 11-25; 68(11-12):927-50. PubMed ID: 16020185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncertainty and variability in the exposure reconstruction of chemical incidents--the case of acrylonitrile.
    Huizer D; Ragas AM; Oldenkamp R; van Rooij JG; Huijbregts MA
    Toxicol Lett; 2014 Dec; 231(3):337-43. PubMed ID: 25050995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtual tissues in toxicology.
    Shah I; Wambaugh J
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):314-28. PubMed ID: 20574905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative interpretation of human biomonitoring data.
    Clewell HJ; Tan YM; Campbell JL; Andersen ME
    Toxicol Appl Pharmacol; 2008 Aug; 231(1):122-33. PubMed ID: 18589468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state solutions to PBPK models and their applications to risk assessment I: Route-to-route extrapolation of volatile chemicals.
    Chiu WA; White P
    Risk Anal; 2006 Jun; 26(3):769-80. PubMed ID: 16834633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
    Thompson CM; Sonawane B; Barton HA; DeWoskin RS; Lipscomb JC; Schlosser P; Chiu WA; Krishnan K
    J Toxicol Environ Health B Crit Rev; 2008 Aug; 11(7):519-47. PubMed ID: 18584453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment.
    Wetmore BA; Wambaugh JF; Ferguson SS; Sochaski MA; Rotroff DM; Freeman K; Clewell HJ; Dix DJ; Andersen ME; Houck KA; Allen B; Judson RS; Singh R; Kavlock RJ; Richard AM; Thomas RS
    Toxicol Sci; 2012 Jan; 125(1):157-74. PubMed ID: 21948869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconstructing exposures from biomarkers using exposure-pharmacokinetic modeling--A case study with carbaryl.
    Brown K; Phillips M; Grulke C; Yoon M; Young B; McDougall R; Leonard J; Lu J; Lefew W; Tan YM
    Regul Toxicol Pharmacol; 2015 Dec; 73(3):689-98. PubMed ID: 26545325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1-trichloroethane.
    Lu Y; Rieth S; Lohitnavy M; Dennison J; El-Masri H; Barton HA; Bruckner J; Yang RS
    Regul Toxicol Pharmacol; 2008 Mar; 50(2):249-60. PubMed ID: 18226845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.